Navigation Links
PharmAthene Reports Third Quarter 2009 Financial and Operational Results
Date:11/12/2009

es, and with preparing and submitting various bids and proposals, along with increased non-cash, stock-based compensation costs for the nine month period.

For the third quarter of 2009, PharmAthene's net loss was $14.0 million, or $0.50 per share, compared to $4.3 million or $0.20 per share, in the same period of 2008. For the nine months ended September 30, 2009, the Company's net loss was $26.6 million, or $0.97 per share, compared to $31.2 million, or $1.41 per share in the same period of 2008.

On July 28, 2009, PharmAthene issued 2-year, 10% unsecured senior convertible notes and common stock purchase warrants ("New Convertible Notes and Warrants") in a private placement in the aggregate principal amount of approximately $19.3 million. This private placement included the issuance of $10.5 million in New Convertible Notes and Warrants to new investors for cash and $8.8 million in New Convertible Notes and Warrants in exchange for 8% senior unsecured convertible notes due August 3, 2009 ("Old Notes") and accrued interest in the same amount. The New Convertible Notes issued in exchange for the Old Notes were accounted for as an early extinguishment of debt, resulting in a non-cash loss on extinguishment of debt of approximately $4.7 million. The proceeds from the sale of the New Convertible Notes and Warrants were used to repay $5.5 million of our Old Notes that were not exchanged for the New Convertible Notes and Warrants and to repay all outstanding amounts and fees under our existing credit facility.

As of September 30, 2009, available cash, cash equivalents and short term investments were $11.6 million. In addition, billed and unbilled accounts and other receivables were $18.7 million at September 30, 2009. The Company estimates that at its currently projected rate of net cash consumption, the existing sources of cash and cash receipts from contract receivables will be sufficient to fund operations through the end of 2010.'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
2. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
3. PharmAthene Named as Contractor in $13.9 Million Award Notice Published by the Department of Health and Human Services
4. Delaware Court Denies Motion by SIGA Technologies Seeking to Dismiss PharmAthenes Legal Action in Breach of Contract Lawsuit Against SIGA
5. PharmAthene to Present at the BIO CEO & Investor Conference 2008
6. PharmAthene Enhances Executive Leadership Team and Appoints Joan Fusco, Ph.D. Senior Vice President of Operations
7. PharmAthene Completes Pharmacokinetic Studies of Protexia(R); Program on Target for IND Filing in 2008
8. PharmAthene to Present at the Cowen and Company 28th Annual Health Care Conference
9. PharmAthene Signs Definitive Agreement to Acquire Biodefense Vaccines Business From Avecia
10. PharmAthene to Delay Release of Full Year 2007 Financial Results
11. PharmAthene Year-End 2007 Earnings Conference Call and Webcast Scheduled for Monday, March 31, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Houston, TX (PRWEB) January 15, 2014 ... Alzheimer’s disease, and about 1 in 3 seniors will ... ( source ). These jaw-dropping figures have shocked many ... function and, hopefully, help prevent these tragic age-related cognitive ...
(Date:1/15/2014)... Freeslate, Inc ., the leading ... Lupin Limited, one of India’s top five pharmaceutical companies, ... System for high throughput solid form screening. ... a wide range of quality, affordable generic and branded ...
(Date:1/14/2014)... San Diego, CA (PRWEB) January 14, 2014 ... based on the products of cells grown under simulated ... an international license agreement with Suneva Medical, Inc. for ... media (CCM). , This agreement is an ...
(Date:1/14/2014)... BETHESDA, Md. , Jan. 14, 2014  Organovo ... institutes from the National Institutes of Health (NIH) to ... more effective treatments to patients on a faster timeline. ... Translational Sciences (NCATS) and the National Eye Institute (NEI) ...
Breaking Biology Technology:Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3
... If one University of Houston professor has his way, the ... one day soon be put to use in improving the ... , Thanks to a pair of grants from the U.S. ... and his research team have demonstrated ultra-high electrical conductive properties ...
... Saver (ES) NU-480 Biological Safety Cabinet (BSC) is now available in North ... features NuAire,s exclusive TouchLink LCD Control Center, a DC-ECM motor, sloped window, ... ... Plymouth, MN (PRWEB) May 15, 2009 -- The CellGard Energy Saver ...
... May 15 Poniard Pharmaceuticals, Inc. (Nasdaq: ... announced that it has filed a shelf registration statement ... (SEC) that, when declared effective by the SEC, will ... sell up to $60 million aggregate amount of its ...
Cached Biology Technology:Inexpensive plastic used in CDs could improve aircraft, computer electronics 2Inexpensive plastic used in CDs could improve aircraft, computer electronics 3CellGard ES NU-480 Class II Biological Safety Cabinet Now Available 2Poniard Pharmaceuticals Files Shelf Registration 2Poniard Pharmaceuticals Files Shelf Registration 3
(Date:4/17/2014)... Down syndrome - or trisomy 21 - is the ... from a chromosomal abnormality where cells of affected individuals ... the human genome). A study conducted by Stylianos Antonarakis ... and Development at the University of Geneva (UNIGE) Faculty ... on how the extra chromosome 21 upsets the equilibrium ...
(Date:4/17/2014)... House honored Clemson professor Rajendra Singh Thursday as ... promote and expand solar deployment in the residential, ... Houser Banks Professor of Electrical and Computer Engineering ... is considered a local hero leading the charge ... opportunity in solar power and driving policy changes ...
(Date:4/17/2014)... many serious conditions such as heart disease, epilepsy and ... therapies. Unfortunately, there is still much scientists do not ... and unexpected insight into the structure of sodium channels ... - which are responsible for ,fine-tuning, the activity of ... recent edition of the Journal of Biological Chemistry ...
Breaking Biology News(10 mins):Trisomy 21: How an extra little chromosome throws the entire genome off balance 2Trisomy 21: How an extra little chromosome throws the entire genome off balance 3White House honors Clemson professor as 'Champion of Change' for solar deployment 2Structure of sodium channels different than previously believed 2
... intravenously could be used as an agent to protect ... radiation in the event of large-scale exposure from a ... presented today by University of Pittsburgh researchers at the ... Radiology and Oncology (ASTRO) in Philadelphia. , "Ionizing radiation ...
... chemicals in the environment can damage the developing brain ... disorder (ADHD), and mental retardation. Still, there has been ... can cause injury to the developing brains of children. ... in The Lancet on November 8, 2006, and in ...
... vaccinating mice with embryonic stem cells prevented lung cancer ... into them after the vaccination or that had been ... suggest that it could be possible to develop embryonic ... as hereditary breast and colon cancer and lung cancer ...
Cached Biology News:Intravenous gene therapy protects normal tissue of mice during whole-body radiation 2A silent pandemic: Industrial chemicals are impairing the brain development of children worldwide 2A silent pandemic: Industrial chemicals are impairing the brain development of children worldwide 3A silent pandemic: Industrial chemicals are impairing the brain development of children worldwide 4Vaccination with embryonic stem cells prevents lung cancer in mice 2Vaccination with embryonic stem cells prevents lung cancer in mice 3
Human DEP-1/CD148 Fluorescein MAb (Clone 143-41) Protein Family: Granulocyte Markers, Monocyte Markers, Phosphatases & Regulators, Other Dendritic Cell Molecules...
An excellent carbonyl-reactive FRET quencher paired with Trp or Tyr. Minimum Purity: 95%. Abs(max): ~350 nm; Em(max): none. Solvent System:DMSO or DMF....
...
...
Biology Products: